1. Home
  2. SAP vs AMGN Comparison

SAP vs AMGN Comparison

Compare SAP & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SAP  SE ADS

SAP

SAP SE ADS

N/A

Current Price

$234.04

Market Cap

238.0B

Sector

Technology

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$464.56

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SAP
AMGN
Founded
1972
1980
Country
Germany
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.0B
251.6B
IPO Year
1996
2002

Fundamental Metrics

Financial Performance
Metric
SAP
AMGN
Price
$234.04
$464.56
Analyst Decision
Buy
Hold
Analyst Count
16
34
Target Price
$284.50
★ $431.81
AVG Volume (30 Days)
2.4M
★ 2.5M
Earning Date
10-21-2026
11-03-2026
Dividend Yield
0.91%
★ 2.17%
EPS Growth
N/A
★ 88.23
EPS
N/A
★ 14.79
Revenue
N/A
★ $25,424,000,000.00
Revenue This Year
$9.92
$7.39
Revenue Next Year
$12.01
$4.46
P/E Ratio
★ $28.01
$31.49
Revenue Growth
N/A
★ 8.83
52 Week Low
$144.97
$312.39
52 Week High
$255.90
$483.99

Technical Indicators

Market Signals
Indicator
SAP
AMGN
Relative Strength Index (RSI) 55.08 62.04
Support Level $227.11 $326.58
Resistance Level $243.05 N/A
Average True Range (ATR) 4.42 12.20
MACD -0.71 0.15
Stochastic Oscillator 37.77 58.07

Price Performance

Historical Comparison
SAP
AMGN

About SAP SAP SE ADS

Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: